Figure 2.

Correlation between genotype and platelet inhibition ratio (PIR) and high on‐treatment platelet reactivity (HPR). (A) HPR rate of patients with CYP2C19*3 was significantly higher than that of patients with CYP2C19*2 and ABCB1 3435CT. (B) Average PIR of patients with CYP2C19*3 was significantly lower than that of patients with CYP2C19*2 and ABCB1 3435CT. PIR: platelet inhibition ratio; HPR: high on‐treatment platelet reactivity. **P < .01, ***P < .001, compared with CYP2C19*3 group. CYP2C19: cytochrome P450 family 2 subfamily C member 19; CYP2C19*2: rs4244285; CYP2C19*3: rs4986893; ABCB1: ATP binding cassette subfamily B member 1; ABCB1 3435CT: rs1045642